2012/02/15 by Eric J. Moore, Michael L. Hinni, Kerry D. Olsen +3 · 1 citation
Medicine · #Head and Neck Cancer Studies #Esophageal Cancer Research and Treatment #Voice and Speech Disorders
paper · doi:10.1177/0194599812437534
openalex publication_date 2012/02/15 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/07
OBJECTIVES: To determine the cost of treatment of oropharyngeal squamous cell carcinoma (OP SCCA) with transoral surgery with concomitant neck dissection (TOS), TOS with adjuvant radiation therapy (TOS + RT), TOS with adjuvant chemoradiation therapy (TOS + CRT), and primary chemoradiation therapy (CRT). STUDY DESIGN: Case series. SETTING: Two tertiary care teaching hospitals. SUBJECTS AND METHODS: Using the databases of 2 teaching hospitals, patients were identified who had OP SCCA treated with TOS, TOS + RT, TOS + CRT, and primary CRT in 2009 to 2010. Costs were analyzed from an institutional perspective looking at reimbursement. Patients with government payers and patients with private payers in each group were identified, and net revenue data obtained for the 3-month period from diagnosis were calculated and averaged for each group. Cost was defined as the reimbursement for all charges surrounding the 3-month episode of treatment. All revenue associated with inpatient and outpatient care, including pharmacy charges, was included. RESULTS: The mean cost of TOS (private payers/government payers) was 37,435/15,664 (range, 22,486-48,746/13,325-16,885). The mean cost of TOS + RT (private payers/government payers) was 74,484/34,343 (range, 72,400-84,825/31,565-40,810). The mean cost of TOS + CRT (private payers/government payers) was 191,780/53,245 (range, 145,450-217,220/49,400-58,325). The mean cost of CRT (private payers/government payers) was 198,285/57,429 (range, 168,216-298,945/52,900-59,545). CONCLUSION: An algorithm of transoral surgical treatment of OP SCCA with adjuvant treatment as indicated by pathology is more cost conscious than an algorithm of treatment of all OP SCCA with CRT.